BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 14967002)

  • 1. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.
    Alvarez-Diez TM; Zheng J
    Chem Res Toxicol; 2004 Feb; 17(2):150-7. PubMed ID: 14967002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
    Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
    Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice.
    He K; Iyer KR; Hayes RN; Sinz MW; Woolf TF; Hollenberg PF
    Chem Res Toxicol; 1998 Apr; 11(4):252-9. PubMed ID: 9548795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.
    O'Donnell JP; Dalvie DK; Kalgutkar AS; Obach RS
    Drug Metab Dispos; 2003 Nov; 31(11):1369-77. PubMed ID: 14570769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes.
    Masubuchi Y; Horie T
    Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor.
    Chiba M; Nishime JA; Lin JH
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1527-34. PubMed ID: 8531125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion.
    Crowley JR; Hollenberg PF
    Drug Metab Dispos; 1995 Aug; 23(8):786-93. PubMed ID: 7493543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of cytochrome P450 2E1 by tert-butylisothiocyanate.
    Kent UM; Roberts ES; Chun J; Hodge K; Juncaj J; Hollenberg PF
    Chem Res Toxicol; 1998 Oct; 11(10):1154-61. PubMed ID: 9778311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2.
    Chang TK; Chen J; Lee WB
    J Pharmacol Exp Ther; 2001 Dec; 299(3):874-82. PubMed ID: 11714871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
    Lin HL; Kent UM; Hollenberg PF
    J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of cytochrome P450 2E1 by benzyl isothiocyanate.
    Moreno RL; Kent UM; Hodge K; Hollenberg PF
    Chem Res Toxicol; 1999 Jul; 12(7):582-7. PubMed ID: 10409397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin.
    Chun YJ; Ryu SY; Jeong TC; Kim MY
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):389-93. PubMed ID: 11259321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based inactivation of cytochrome P450 2B1 by N-benzyl-1-aminobenzotriazole.
    Kent UM; Bend JR; Chamberlin BA; Gage DA; Hollenberg PF
    Chem Res Toxicol; 1997 May; 10(5):600-8. PubMed ID: 9168259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases.
    Sridar C; Goosen TC; Kent UM; Williams JA; Hollenberg PF
    Drug Metab Dispos; 2004 Jun; 32(6):587-94. PubMed ID: 15155549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
    Karjalainen MJ; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2006 Dec; 34(12):2091-6. PubMed ID: 16985100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
    Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
    Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of benzyl isothiocyanate on rat and human cytochromes P450: identification of metabolites formed by P450 2B1.
    Goosen TC; Mills DE; Hollenberg PF
    J Pharmacol Exp Ther; 2001 Jan; 296(1):198-206. PubMed ID: 11123381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and selectivity of mechanism-based inhibition of guinea pig hepatic and pulmonary cytochrome P450 by N-benzyl-1-aminobenzotriazole and N-alpha-methylbenzyl-1-aminobenzotriazole.
    Sinal CJ; Bend JR
    Drug Metab Dispos; 1996 Sep; 24(9):996-1001. PubMed ID: 8886610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
    McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
    Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
    Avent KM; DeVoss JJ; Gillam EM
    Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.